Yaron Arbel

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker et al. · The Lancet · 2020 · 761 citations · Full text

Medicine, Cardiology, Iron Metabolism Disorders +11

Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice

Yehuda Kamari, Aviv Shaish, Einav Vax et al. · Journal of Hepatology · 2011 · 285 citations · Full text

Life Sciences, Immunology, Pathology +12

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Carolyn S.P. Lam, Anna Giczewska, Karen Sliwa et al. · JAMA Cardiology · 2020 · 82 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Whole-exome sequencing in individuals with multiple cardiovascular risk factors and normal coronary arteries

Yigal Abramowitz, Arie Roth, Gad Keren et al. · Coronary Artery Disease · 2016 · 23 citations

Medicine, Cardiology, Genetics +17